In the latest trading session, Fibrocell Science closed at $2.30, marking no change from the previous day. This move lagged the S&P 500's daily gain of 0.1%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq lost 0.66%.
Heading into today, shares of the biotechnology company that specializes in treatments for skin and tissue had gained 21.69% over the past month, outpacing the Medical sector's loss of 4.88% and the S&P 500's gain of 3.95% in that time.
Wall Street will be looking for positivity from FCSC as it approaches its next earnings report date. In that report, analysts expect FCSC to post earnings of -$0.33 per share. This would mark year-over-year growth of 40%.
Investors might also notice recent changes to analyst estimates for FCSC. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 16.67% higher. FCSC currently has a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 78, putting it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow FCSC in the coming trading sessions, be sure to utilize Zacks.com.